Antacids May Improve Blood Sugar Control in People with Diabetes

Antacids improved blood sugar control in people with diabetes but had no effect on reducing the risk of diabetes in the general population, according to a new meta-analysis published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.

Type 2 diabetes is a global public health concern affecting almost 10 percent of people worldwide. Doctors may prescribe diet and lifestyle changes, diabetes medications, or insulin to help people with diabetes better manage their blood sugar, but recent data points to common over the counter antacid medicines as another way to improve glucose levels.

“Our research demonstrated that prescribing antacids as an add-on to standard care was superior to standard therapy in decreasing hemoglobin A1c (HbA1c) levels and fasting blood sugar in people with diabetes,” said study author Carol Chiung-Hui Peng, MD, of the University of Maryland Medical Center Midtown Campus in Baltimore, Md.

“People with diabetes should be aware that these commonly used antacid medications may improve their blood sugar control, and providers could consider this glucose-lowering effect when prescribing these medications to their patients.” – Kashif Munir, MD, associate professor, Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, Md.

“For people without diabetes, taking antacids did not significantly alter their risk of developing the disease,” said study author, Huei-Kai Huang, MD, of the Hualien Tzu Chi Hospital in Hualien, Taiwan.

The researchers performed a meta-analysis on the effects of proton pump inhibitors (PPIs)—a commonly used type of antacid medication—on blood sugar levels in people with diabetes and whether these medications could prevent the new onset of diabetes in the general population. The analysis included seven studies (342 participants) for glycemic control and five studies (244, 439 participants) for risk of incident diabetes. The researchers found antacids can reduce HbA1c levels by 0.36% in people with diabetes and lower fasting blood sugar by 10 mg/dl based on the results from seven clinical trials. For those without diabetes, the results of the five studies showed that antacids had no effect on reducing the risk of developing diabetes.

“People with diabetes should be aware that these commonly used antacid medications may improve their blood sugar control, and providers could consider this glucose-lowering effect when prescribing these medications to their patients,” said study author Kashif Munir, MD, associate professor in the division of endocrinology, diabetes and nutrition at the University of Maryland School of Medicine in Baltimore, Md.

Other authors of the study include: Yuting Huang and Khulood Bukhari of the University of Maryland Medical Center Midtown Campus in Baltimore, Md.; Yu-Kang Tu of the National Taiwan University and the Taipei Medical University in Taipei, Taiwan; Gin Yi Lee of the Danbury Hospital in Danbury, Conn.; Rachel Huai-En Chang of the Johns Hopkins Bloomberg School of Public Health in Baltimore, Md.; Yao-Chou Tsai of the Taipei Medical University; Yunting Fu of the University of Maryland in Baltimore, Md.

The manuscript received no external funding.

The manuscript, “Effects of Proton Pump Inhibitors on Glycemic Control and Incident Diabetes: A Systematic Review and Meta-analysis,” was published online, ahead of print.

You may also like

  • Heroin Adulterated with Diabetes Medication Triggers Life-Threatening Medical Emergencies

    Medical researchers have identified a dangerous and deceptive trend in the illicit drug market after two nondiabetic patients were admitted to intensive care with life-threatening hypoglycemia following heroin use. The cases, occurring years apart but linked by the same rare clinical presentation, reveal that heroin supplies are being contaminated with glipizide, a potent prescription medication…

  • Hyperinsulinemia Emerges as Critical Predictor of Severe Liver Outcomes

    Researchers have identified fasting hyperinsulinemia as a primary, yet often overlooked, driver of metabolic dysfunction-associated steatotic liver disease (MASLD). A new review published in Hepatology suggests that elevated insulin levels are not merely a symptom of metabolic syndrome but a direct contributor to liver fibrosis and a potent predictor of major adverse liver and cardiovascular…